Rosetta Genomics Licenses microRNAs From Rockefeller University

Jun 14, 2007

NEW YORK (GenomeWeb News) — Rosetta Genomics has struck an agreement to use some of Rockefeller University’s viral and human microRNAs for therapeutic uses, the company said Wednesday.

Rosetta Genomics President and CEO Amir Avniel said the microRNAs offer the company access to more potential drug targets, and is in line with the its strategy to supplement its own research through licensing agreements with key academic centers.

The company said it now has the rights to more than 500 microRNA targets.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Featured White Papers

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

May

08

Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

Main menu